Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD

Published:2014-05 Issue:5 Volume:145 Page:981-991
ISSN:0012-3692
Container-title:Chest
language:en
Short-container-title:Chest

Author:

Celli Bartolome,Crater Glenn,Kilbride Sally,Mehta Rashmi,Tabberer Maggie,Kalberg Chris J.,Church Alison

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference36 articles.

1. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper;Celli;Eur Respir J,2004

2. Reducing cholinergic constriction: the major reversible mechanism in COPD;Brusasco;Eur Respri Rev,2006

3. The role of anticholinergics in chronic obstructive pulmonary disease;Barnes;Am J Med,2004

4. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD;Cazzola;Pulm Pharmacol Ther,2010

5. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison;Mahler;Thorax,2012

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Umeclidinium plus vilanterol versus fluticasone propionate plus salmeterol for chronic obstructive pulmonary disease: a meta-analysis of randomized, controlled trials;Postgraduate Medical Journal;2024-04-23

2. Network meta-analysis of the efficacy and safety of monoclonal antibodies and traditional conventional dichotomous agents for chronic obstructive pulmonary disease;Frontiers in Medicine;2024-02-13

3. Comparison of Clinical Outcomes Among Different Fixed-Dose Combinations of Long-Acting Muscarinic Antagonists and Long-Acting β2-Agonists in Patients With COPD;Chest;2023-04

4. Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD;Journal of Clinical Medicine;2022-12-01

5. Double broncholytic combination of umeclidnium/ vilanterol in COPD therapy: issues of efficacy and safety;Meditsinskiy sovet = Medical Council;2022-10-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3